From the covid pill to the flu vaccine Vaxart is making a name for itself as a revolutionary disruptor in the vaccine industry. Phase 2 clinical trials began in the third quarter for VXRT’s oral vaccine candidate with an expected completion date of spring 2022. Results from the Phase II human influenza challenge trial showed that those who were given VXA-A1.1 were better at providing protection against viral shedding compared to the injected inactivated influenza vaccine (IIV). All this while stock prices show a squeeze at the end of a pattern. Will Vaxart blow past resistance or crash through support? Let’s find out.

Welcome to Money Talk Sundayz. I’m your Investment Bro Stevie Bee. I hope you enjoyed my last VXRT episode. Run that like share and subscribe button. Let’s get to it.

A new study shows that there might be a way to protect against influenza infection without needing to stir up antibody response. Scientists from Stanford University investigated the effectiveness of an oral tablet flu vaccine called VXA-A1.1 by Vaxart, which uses cellular correlates of protection. Results from the Phase II human influenza challenge trial showed that those who were given VXA-A1.1 were better at providing protection against viral shedding compared to the injected inactivated influenza vaccine (IIV).

Those who received VXA-A1.1 were found with plasmablasts and hemagglutinin (HA+)-specific cells that contributed to protection from viral shedding after 90 days. This was not seen in those who got IIV or a placebo. On day 8, those who were given the oral drug demonstrated T cell expressing markers that suggested enhanced mucosal tissue homing.

Details of the VXA-A1.1 study are published in Cell Host and Microbe.

On the Covid front, the company began the first Phase II trial of their investigational COVID-19 oral tablet vaccine and dosed the first participants. The whole data set from this investigation is expected to be accessible in Q1 2022, according to Vaxart.

Published results by Duke University show that the company’s COVID-19 vaccine candidate reduced airborne transmission of the SARS-CoV-2 virus in a preclinical animal model. Vaxart also improved its research and manufacturing capacity, allowing it to move forward with the production of the vaccine candidate.

CEO Andrei Floroiu stated, “Vaxart made significant progress this quarter toward its goal of developing a next-generation oral tablet COVID-19 vaccine. We have started our United States Phase II trial and anticipate beginning international trials in the near future. This is an important milestone, as our candidate is the only oral COVID-19 vaccine to progress to Phase II trials in the U.S.”

Vaxart founder and Chief Scientific Officer Dr. Sean Tucker said The progress we made in our vaccine research this quarter was significant. We already learned from an earlier human influenza challenge study that our oral flu vaccine candidate inhibited the shedding of viral RNA better than injectable vaccines. In addition, our published hamster study showed that our vaccine candidate could reduce transmission of SARS-CoV-2, even when there is an infection breakthrough in a vaccinated subject. The implications are significant because existing injected vaccines do not always protect against viral shedding and transmission to other people.”

Vaxart Inc. stock is now 23.64% up from its year-to-date (YTD) trading value. VXRT Stock saw the intraday high of $7.29 and lowest of $6.77 per share.

Compared to the average trading volume of 3.53M shares, VXRT reached a trading volume of 5943937 in the most recent trading day, which is why market watchdogs consider the stock to be active.

With this latest performance, VXRT shares gained by 2.32% in over the last four-week period, additionally plugging by 5.37% over the last 6 months – not to mention a rise of 23.86% in the past year of trading.